Sani H. Kizilbash - Concepedia

Author

Sani H. Kizilbash

Also Known As

S H Kizilbash, S Kizilbash, S. H. Kizilbash, S. Kizilbash, S.H. Kizilbash, Sani H. Kizilbash, Sani H Kizilbash, Sani H. Kizilbash, Sani Haider Kizilbash, Sani Kizilbash

219

Publications

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic Mayo Clinic in Arizona WinnMed Mayo Clinic in Florida Mayo Clinic Hospital

About

Sani H. Kizilbash is an author at Mayo Clinic specializing in medicine, glioma, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	436
2	Health Sciences	8	8	314
3	Social Sciences	1	1	30
4	Biochemistry	1	1	17
5	Cell Biology	1	1	86

Sani H. Kizilbash

Publications

975

Citations

H-Index

Page 1

	Year	Citations
Delineation of<i>MGMT</i>Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma Shiv K. Gupta, Sani H. Kizilbash, Brett L. Carlson, JNCI Journal of the National Cancer Institute	2015	120
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System Karen E. Parrish, Ling Cen, J. C. Murray, Molecular Cancer Therapeutics PharmacotherapyHigh-grade GliomasGliomaTumor BiologyNeuro-oncology	2015	86
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity Shiv K. Gupta, Emily J. Smith, Ann C. Mladek, Frontiers in Oncology	2019	79
Discordant <i>In Vitro</i> and <i>In Vivo</i> Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts Shiv K. Gupta, Ann C. Mladek, Brett L. Carlson, Clinical Cancer Research	2014	76
The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study Andres Ramos‐Fresnedo, Michael W. Pullen, Carlos Perez‐Vega, Journal of Neuro-Oncology Neuro-oncologyGliomaTumor HeterogeneityMedicineMolecular Glioblastoma Idh-wildtype	2022	72
Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma Sani H. Kizilbash, Shiv K. Gupta, Kenneth Tou En Chang, Molecular Cancer Therapeutics	2017	71
Initial Results of a Phase 2 Trial of 18F-DOPA PET-Guided Dose-Escalated Radiation Therapy for Glioblastoma Nadia N. Laack, Deanna Pafundi, S. Keith Anderson, International Journal of Radiation OncologyBiologyPhysics Neuro-oncologyInitial ResultsMedical ImagingRadiation TherapyMedicine	2021	65
The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma Sani H. Kizilbash, Caterina Giannini, Jesse S. Voss, Journal of Neuro-Oncology Radiation TherapyMedicineIdh Mutation StatusPathologyAdjuvant Radiation	2014	40
Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma Alyx B. Porter, Heshan Liu, Sadhna Kohli, JAMA Oncology	2021	36
Seizures in patients with primary brain tumors: what is their psychosocial impact? John Y. Shin, Sani H. Kizilbash, Steven I. Robinson, Journal of Neuro-Oncology Neuro-oncologyNeuropsychologyPsychosocial ImpactPsychiatryNeurological Disorder	2016	30

Page 1